Risk factors for adverse outcomes of Indigenous infants hospitalized with bronchiolitis by McCallum, Gabrielle et al.
Pediatric Pulmonology 51:613–623 (2016)
Risk Factors for Adverse Outcomes of Indigenous Infants
Hospitalized With Bronchiolitis
Gabrielle B. McCallum, PhD,1* Mark D. Chatfield, Msc,1 Peter S. Morris, PhD,1,2
and Anne B. Chang, PhD1,3
Summary. Background: Hospitalized bronchiolitis imposes a significant burden among infants,
particularly among Indigenous children. Traditional or known risk factors for severe disease are
well described, but there are limited data on risks for prolonged hospitalization and persistent
symptoms. Our aims were to determine factors (clinical and microbiological) associated with (i)
prolonged length of stay (LOS); (ii) persistent respiratory symptomsat 3weeks; (iii) bronchiectasis
up to 24 months post-hospitalisation; and (iv) risk of respiratory readmissions within 6 months.
Methods: Indigenous infants hospitalized with bronchiolitis were enrolled at Royal Darwin Hospital
between 2008 and 2013. Standardized formswere used to record clinical data. A nasopharyngeal
swab was collected at enrolment to identify respiratory viruses and bacteria. Results: The median
age of 232 infants was 5 months (interquartile range 3–9); 65%male. On multivariate regression,
our 12 point severity score (including accessory muscle use) was the only factor associated with
prolonged LOS but the effect wasmodest (þ3.0 hr per point, 95%CI: 0.7, 5.1,P¼0.01). Presence
of cough at 3 weeks increased the odds of bronchiectasis (OR 3.0, 95%CI: 1.1, 7.0, P¼0.03).
Factors associated with respiratory readmissions were: previous respiratory hospitalization (OR
2.3, 95%CI: 1.0, 5.4, P¼0.05) and household smoke (OR 2.6, 95%CI: 1.0, 6.3, P¼0.04).
Conclusion: Increased severity score is associated with prolonged LOS in Indigenous children
hospitalized with bronchiolitis. As persistent symptoms at 3 weeks post-hospitalization are
associated with future diagnosis of bronchiectasis, optimising clinical care beyond hospitalization
is needed to improve long-term respiratory outcomes for infants at risk of respiratory disease.
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INTRODUCTION
Bronchiolitis is typically a self-limiting illness, but
causes considerable morbidity and remains a leading
cause for hospitalization among infants worldwide.1 The
cost of hospitalized bronchiolitis has risen substantially in
the USA over the last decade (increase of 34%).2 There
are many studies that have reported on the risk factors
for severe disease and length of stay (LOS) in hospital,
for example, prematurity and cardio-respiratory disease.3
However, there is relatively little data on other factors
(e.g. detection of bacteria with viruses) associated with
LOS in hospital in an at-risk population (e.g., Indigenous
children who have more severe bronchiolitis)4 and future
bronchiectasis.5
Factors associated with severe illness and/or prolonged
LOS include clinical severity (assessed by scoring
systems), viruses,1,3,6 and secondary bacterial infection.7
Respiratory syncytial virus (RSV) is implicated for
50–80% of cases and is associated with more severe
disease in some studies8–10 but not in others.6 Whether
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single versus multiple viruses influence disease severity is
also controversial.11,12 Further, a number of non-classical
respiratory viruses (e.g. coronaviruses, bocaviruses) have
been identified13 but the clinical relevance of these
remains unclear, as these non-classical viruses are
commonly present in asymptomatic children.14 In a
hospital-based study, a virus (including non-classical
viruses) was detected (42%) in the nasopharynx of
children who did not have any respiratory symptoms.14
Children with severe bronchiolitis requiring intensive
care are likely to have a secondary bacterial infection.7
However, studies on bronchiolitis to date have not
examined whether the presence of respiratory bacteria in
the upper airways influences clinical outcomes in children
hospitalizedwith bronchiolitis. Examination for bacteria is
not routine in bronchiolitis management. However, it is
plausible that secondary bacterial infection that occur post
viral infections15 are more likely when the nasopharynx is
colonizedwith bacteria, as found in some populations such
as in Northern Territory Indigenous infants. In these
children, early (at 2 weeks of age), common (up to 90%
of infants) and dense acquisition of respiratory bacteria
(Streptococcus pneumoniae, Haemophilus influenzae and
Moraxella catarrhalis)16 have been documented. Thus,
in study settings like ours, the presence of bacteria in the
nasopharynx may be particularly relevant. Secondary
bacterial infection may complicate bronchiolitis, and
possibly contribute to poorer long-term outcomes such
as chronic wet cough17 and bronchiectasis.18 It has been
shown in children aged 3 years hospitalized with first
timewheezing, co-detection of viruses (93%) and bacteria
(60%) in nasopharyngeal aspirates resulted in prolonged
LOS.19 Yet, it remains unknown whether co-detection of
bacteria with viruses in the nasopharynx at the point of
bronchiolitis hospitalization contributes to LOS. This data
is lacking and is especially important for populations at
high risk of poorer outcomes (e.g. secondary bacterial
pneumonia, chronic wet cough etc).4,17 Further rationale
for assessing viruses and bacteria in the infants involved
in our studies was described in a previous paper.20
Beyond hospitalization, persistence of respiratory symp-
toms (i.e., post-bronchiolitis syndrome) is increasingly
appreciated.3,21 Cohort studies report symptoms in up
to 40% of infants, 14–25 days post-hospitalization.3,22
There are few data on what happens to these children in the
medium term (4 weeks to 6 months). Determining the
clinical relevance of symptoms beyond hospitalization is
particularly important in populations, for example, Indige-
nous children who have a high risk of bronchiectasis.
In the absence of any data from Indigenous children,
we combined data from three prospective studies that
included 232 Indigenous infants hospitalized with a
clinical diagnosis of bronchiolitis, to examine factors
(clinical and microbiological) on admission that were
associated with (i) prolonged LOS (Aim-1); (ii) presence
of persistent symptoms 3 weeks after hospital discharge
(Aim-2); (iii) whether presence of cough at 3 weeks was
associated with bronchiectasis up to 24 months post-
hospitalisation (Aim-3); and (iv) re-hospitalization within
6 months for a respiratory illness (Aim-4). We hypothe-
sized that co-detection of viruses and/or bacteria in
the nasopharynx is associated with longer LOS, persistent
respiratory symptoms and re-hospitalization with a
respiratory illness within 6 months of discharge.
METHODS
Study Design
Data from three prospective studies were combined
(Fig. 1) for the different aims; two studies were randomized
controlled trials (RCT)5,23 and one a cohort study.24 Here,
we briefly describe these studies as the methods have been
published.5,23,24 Both RCTs aimed to determine if different
durations of azithromycin, compared to placebo, improved
clinical outcomes for infants hospitalized with bronchiolitis
(i.e., LOS, oxygen requirement and respiratory readmis-
sions within 6 months of hospital discharge). The cohort
study aimed to determine the validity and reliability of a
severity scoring system among infants presenting to Royal
Darwin Hospital (RDH) with bronchiolitis (Fig. 1).24 RDH
is a 363 bed referral center, servicing150,000 peoplewith
geographical coverage of 400,000 km.2 Studies were
approved by the Human Research Ethics Committee of
the Northern Territory Department of Health and Menzies
School of Health Research (RCT-1:HREC 07/60; RCT-2
and cohort study: HREC-2010-1324). Written informed
consent was obtained from the carer of each infant.
Most children were involved in the two RCTs; Australian
and New Zealand Clinical Trials Register: Clinical
trials numbers: ACTRN12608000150347 (RCT-1) and
ACTRN12608000150347 (RCT-2).
Study Population
In this study, only Indigenous infants were included
as our previous work showed being Indigenous as an
independent risk factor for more severe bronchiolitis.5
ABBREVIATIONS:
HREC human research ethics committee
HRV human rhinovirus
IQR interquartile range
LOS length of stay
NPS nasopharyngeal swab
OR odds ratio
O2 oxygen
RCT randomised controlled trial
RSV respiratory syncytial virus
SpO2 oxygen saturation
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Infants were eligible if they were from Darwin, 18
months (RCT-1)5 or 24 months old (RCT-2 and cohort
study),23,24 and hospitalized with bronchiolitis. Infants
were excluded if they had very severe disease (admitted
to intensive care), chronic lung disease, congenital heart
disease, contraindications to macrolide use (RCT-1 and
RCT-2), received macrolides (in last 7 days), diarrhoea,
or clinical and radiological features consistent with a
primary diagnosis of pneumonia (as diagnosed by the
attending medical team). Infants were similar and
contributed data only once for this study.
Clinical Assessment and Specimen Collection at
Enrolment
Standardized data collection forms were used to record
demographic, medical history and clinical data (Table 1).
Other therapies and routine investigations were also
documented. Infantswho received additional trialmedication
(e.g., azithromycin) were treated the same for this analysis as
those who received placebo, as no clinically significant
differences in either RCT were observed.5,23 Severity was
assessedusing a scorewevalidated in our setting.24The score
comprised of four components (respiratory rate, accessory
muscle use, degree ofwheezing and SpO2). Each component
scoredbetween0and3, providing a composite score between
0-12. LOS was defined by the treating medical team as time
from admission, to time for “ready for discharge” (Sp02
consistently>94% in air for>16hr) and feeding adequately.
Infants were clinically reviewed by research nurses
(urban-based infants) or at their local health clinic
(remote-based infants) 3 weeks after hospital discharge,
to determine presence of persistent respiratory symptoms
and signs. Remoteness was described as more than
100 km from a tertiary hospital. Any respiratory
readmission and investigations for bronchiectasis were
monitored by a hospital based study (HREC 07/63). As
RDH is the only hospital our target population accesses,
all hospitalizations were accurately captured.
A nasopharyngeal swab (NPS) at enrolment was tested
for common respiratory bacterial pathogens (Streptococ-
cus pneumoniae, Haemophilus influenzae, Moraxella
catarrhalis and Staphylococcus aureus) were identified
on culture,25 and C. pneumoniae and M. pneumoniae on
PCR. Abroad panel of viruses;RSV (AandB), adenovirus,
parainfluenza (1, 2, 3), influenzavirus (A and B), human
rhinovirus (HRV) and enterovirus, coronaviruses,
bocavirus, humanmetapneumovirus (hMPV), KI (KIPyV)
and WU (WUPyV) polyomaviruses were identified by
PCR.5
Statistical Analysis
Data were entered on an Access database and analyzed
using Stata version 13 (StataCorp College Station, TX). As
data were skewed, we log-transformed our main outcome
measure LOS. Exponentiating linear regression coeffi-
cients of log LOS gave us the multiplicative effect
of a risk factor on geometric mean LOS, which
we re-expressed (by assuming the median LOS for the
reference group was 58 hr) as the approximate increase in
median LOS in hours. Logistic regression was used to
examine the association of independent variables on
presence of cough at 3weeks, and respiratory readmissions
within 6 months. All factors with univariate P< 0.2 were
included in multivariable regression models (except for
viruses—RSV was entered and other variables relating to
viruses were not). A two-tailed P 0.05 was considered
significant. As this was a secondary analysis of available
data, sample size calculation was not undertaken.
Fig. 1. Studies where Indigenous infants were recruited at Royal Darwin Hospital.
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RESULTS
Demographic data are summarized in Table 1 for the
232 Indigenous infants included in this study (70% of the
232 were from RCT-1,23 RCT-218%5 and Cohort-12%,24
Fig. 1). Most children were aged 12 months (90%), not
born premature (75% born 37 weeks) and required
O2 supplementation (62%). No child required intensive
care transfer.
From the NPS of 229 Indigenous infants (one refused,
two did not provide consent for NPS), 175 (76%) had one
or more viruses identified. RSV was the most common
followed by HRV, WUPyV and adenovirus (Table 2). At
least one type of respiratory bacteria was detected in
155 (67%) infants. The most common bacteria cultured
was Moraxella catarrhalis, followed by Haemophilus
influenzae, and Streptococcus pneumoniae. The NPS from
24 (10%) infants was negative for both bacteria and virus.
Factors on Admission Associated With Prolonged
LOS (Aim-1)
On univariate analysis, factors on admission signifi-
cantly associated with prolonged LOS were age and
TABLE 1—Demographic and Clinical Characteristics of
(n¼ 232) Indigenous Infants
Demographics
Age (months) 5 (3–9)
Boys 151 (65%)
Gestational age (weeks) 38 (36–39)
Birth weight (kg) 3.0 (2.5–3.3)
Premature (37 weeks) 59 (25%)
Remote 193 (83%)
Currently breastfed 195 (84%)
Previous respiratory hospitalisation 51 (22%)
Mother smoked during pregnancy1 130 (56%)
Exposed to household smoke1 145 (63%)
Symptoms leading up to admission (parent reported)
Days with respiratory symptoms1 3 (2–4)
Nasal discharge 196 (85%)
Cough 228 (98%)
Breathing difficulties 228 (98%)
Poor feeding 95 (41%)
Lethargy 136 (59%)
Severity score (composite score (0–12))23 5 (3–7)
Enrolment observations
Number on oxygen 144 (62%)
Level of supplemental O2 (L/min) 1 (0.5, 2)
Heart rate (beats/min) 143 (132–155)
Temperature (8C) 37.0 (36.0–37.0)
Antibiotics prescribed prior to hospital1 116 (57%)
Antibiotics prescribed during hospital 201 (87%)
Supplemental IV fluid administered 64 (28%)
Chest X-ray taken 217 (94%)
Any virus detected1 175 (76%)
Any bacteria present1 155 (67%)
Any co-morbidity
1,2
131 (56%)
Hospitalisation
Length of stay (hours) 58 (43–85)
Supplemental O2 required 144 (62%)
Time on supplemental O2 (hours) 43 (23–74)
Post-hospitalisation data
Cough present at 3 weeks post-hospitalisation1 31/157 (20%)
Presence of any respiratory abnormality
3 weeks post-hospitalisation1
32/157 (20%)
Presence of otitis media 3 weeks post-
hospitalisation1
21/143 (15%)
Re-hospitalisation for any respiratory illness
within 6 months
48/204 (24%)
CT-confirmed bronchiectasis 30/157 (19%)
Baseline demographics and clinical characteristics of indigenous
infants hospitalized with bronchiolitis.
Data presented as median and IQR for continuous variables, and actual
numbers for categorical variables and percentages.
1Missing data–; Gest age, 16;Weight, 22; Mother smoke, 4; Household
smoke, 2; Days with respiratory symptoms, 3; Poor feeding, 1;
Lethargy, 3; Pulse, 2; Temperature, 5; Ox (L/min), 25; Nasopharyngeal
swab, 3 refused/did not collect. Severity score, 42 infants (one study did
not collect). Three-week post hospital, 157 (only one study collected
this data); n¼ 5 did not complete review.
2Co-morbidity, any otitis media, skin infection, or lobar pneumonia/
collapse.
TABLE 2—Distributionb of Viruses, Atypical Bacteria and
Bacteria Detected at Enrolment With NPS
Virus and atypical
bacteria
Number of children with micro-organism
detected (% of N¼ 229)
No virus detected 54 (24%)
1 Virus detected 123 (54%)
2 Or more viruses
detected
52 (23%)
RSV 98 (43%)
HRV 61 (27%)
Adenovirus 15 (7%)
WUPyV 15 (7%)
Influenza_AB 10 (4%)
hMPV 7 (3%)
Bocavirus 5 (2%)
Coronavirus 3 (1%)
Parainfluenza_123 4 (2%)
Enterovirus 4 (2%)
KIPyV 4 (2%)
C. pneumoniae 4 (2%)
M. pneumoniae 0 (0%)
RSV and HRV 144 (63%)
Bacteria
No bacteria
detected
76 (33%)
1 Type of bacteria
detected
90 (39%)
2 Or more
bacteria detected
65 (28%)
Moraxella
catarrhalis
89 (39%)
Haemophilus
influenzae
88 (34%)
Streptococcus
pneumoniae
50 (22%)
Staphylococcus
aureus
24 (10%)
Detection of viruses, atypical bacteria and bacteria detected at
enrolment in NPS.
Many children had more than one organism detected.
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severity score (Table 3). Notably, antibiotics prior to
hospitalization, any virus and co-detection of virus/
bacteria were not associated with longer LOS. On
multivariate regression, the only factor that remained
significant was severity score. Detection of RSV
increased LOS by 10 hr (P¼ 0.06), but this did not reach
statistical significance. We then examined which compo-
nent of the severity score contributed the most to LOS
(Table 4). In the univariate analysis, (considering each of
the four components as single factors) all components
TABLE 3—Analysis of Risk Factors for LOS (nmax¼ 232)
Univariate Multivariate
Risk factors present on
admission
Difference in
median LOS
(hours) 95%CI P-value
Difference in
median LOS
(hours) 95%CI P-value
Continuous Spearman
correlation
Age (months) 0.2 1.2 (2.1, 0.2) 0.02 0.6 (1.6, 0.5) 0.3
Gestational age (weeks) 0.09 0.7 (0.7, 2.0) 0.3
Birth weight (kg) 0.03 0.0 (5.7, 6.2) 0.9
Severity score on
admission (points)
0.2 3.1 (1.1, 5.1) 0.002 3.0 (0.7, 5.1) 0.01
Categorical Geometric mean
LOS (hours)
Gender
Female 61 1.4 (9.4, 8.0) 0.8
Male 62 (reference)
Currently breastfed
Yes 62 1.9 (8.9, 15.1) 0.7
No 60 (reference)
Previous respiratory hospitalisation
Yes 60 2.0 (11.1, 9.0) 0.7
No 62 (reference)
Mother smoked during pregnancy
Yes 62 1.7 (6.6, 11.4) 0.7
No 60 (reference)
Exposed to household smoke
Yes 62 0.2 (8.0, 9.8) 0.9
No 61 (reference)
Antibiotics before hospitalisation
Yes 61 7.1 (14.4, 1.4) 0.09 2.4 (11, 7.6) 0.6
No 69 (reference)
Any virus detected
Yes 64 8.7 (1.9, 21.3) 0.11
No 55 (reference)
RSV
Yes 66 7.0 (2.2, 17.2) 0.14 10.0 (0.6, 22.3) 0.06
No 58 (reference)
HRV
Yes 64 3.4 (6.1, 14.6) 0.5
No 61 (reference)
RSV and HRV
Yes 64 5.0 (3.8, 15.1) 0.3
No 59 (reference)
Adenovirus
Yes 57 4.4 (18.3, 14.3) 0.6
No 62 (reference)
Any bacteria detected
Yes 63 3.1 (5.7, 13.4) 0.5
No 59 (reference)
Virus/bacteria interaction 0.3
Virus negative/Bacteria negative 58 (reference)
Virus negative/Bacteria positive 53 5.0 (19.1, 14.2) 0.6
Virus positive/Bacteria negative 60 1.5 (13.2, 21.0) 0.9
Virus positive/Bacteria positive 65 7.0 (7.9, 26.0) 0.4
On univariate analysis, factors at enrolment associated with prolonged LOS were age and severity score. On multivariate analysis, only severity
score remained significant.
Arising as a re-expression of the multiplicative effect on the geometric mean from a linear regression on log (LOS).
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except wheeze were significantly associated with pro-
longed LOS. On multivariate regression, only the
“accessory muscle use” component remained significant.
We repeated the main analyses, restricting the cohort to
the n¼ 181 infants who had no previous respiratory
hospitalizations. On multivariate analysis, the only factor
which significantly prolonged LOS was the severity score
(P¼ 0.02).
PresenceofCough3WeeksAfter Discharge (Aim-2)
One hundred and fifty seven Indigenous infants who
had a clinical review at 3 weeks contributed to this
analysis (Fig. 1). Persistent respiratory symptoms were
frequent beyond hospitalization (Table 1). On univariate
analysis, factors significantly associated with presence of
cough 3 weeks after discharge was age and presence
of “any bacteria” cultured on NPS. No factors remained
significant on multivariate regression.
Presence of Cough 3 Weeks After Discharge and
the Relationship to Bronchiectasis (Aim-3)
As of 7th May 2015, 30/157 (19%) infants had a chest
CT scan requested by their treating pediatrician for clinical
reasons when seen 7 months (interquartile range (IQR)
2–13) post-hospitalization for bronchiolitis. All 30 (100%)
children had bronchiectasis documented in the CT scan,
performed at median 13months (IQR 7–18) post the index
bronchiolitis hospitalization. Infants with persistent cough
at 3 weeks after hospitalization were significantly more
likely to have bronchiectasis compared to those without a
cough (OR 3.0, 95%CI: 1.1–7.0, P¼ 0.03).
Respiratory Readmissions 6 Months After
Discharge (Aim-4)
On univariate analysis, factors that significantly
increased the odds of respiratory readmission 6-months
after discharge were previous respiratory hospitalization
TABLE 4—Analysis of the Different Components of the Severity Score Contributing to LOS (n¼ 190)
Univariate analysis Multivariate analysis
Points Component n
Geometric
mean LOS
Difference in
median LOS
(hours) 95%CI P-value
Difference in
median LOS
(hours) 95%CI P-value
Respiratory rate
0 <30 3 58 (reference)
1 30–45 73 54 4 (29.1, 42.0) 0.8
2 45–60 70 60 2 (26.0, 53.2) 0.9
3 >60 44 73 16 (18.8, 80.0) 0.5
Wheeze
0 None 85 63 (reference)
1 Expiration only 37 56 6 (15.7, 6.4) 0.3
2 Entire expiration and
inspiration with
stethoscope
30 52 10 (20.0, 1.9) 0.09
3 Entire expiration and
inspiration without
stethoscope
38 66 3 (8.4, 17.2) 0.6
SpO2
0 >95 148 58 (reference)
1 94–95 14 59 2 (13.8, 22.2) 0.9
2 90–93 24 69 11 (3.1, 29.7) 0.1
3 <89 4 97 40 (1.1, 109.3) 0.06
Accessory muscle use
0 None 15 50 (reference)
1 þ 64 53 4 (12.0, 26.0) 0.6
2 þþ 66 60 12 (5.9, 36.5) 0.2
3 þþþ 45 76 31 (7.6, 63.9) 0.007
Per one point increase
per component
Respiratory rate 9.0 (2.7, 15.4) 0.004 4.7 (1.9, 12.0) 0.2
Wheeze 0.2 (3.9, 3.7) 0.9 1.8 (5.3, 2.0) 0.4
SpO2 7.0 (0.5, 13.2) 0.03 4.5 (1.4, 11.0) 0.14
Accessory muscle use 10.0 (4.4, 15.7) 0.0001 7.0 (0.7, 13.8) 0.03
In the univariate analysis, all four components except wheeze contributed to prolonged LOS. On multivariate regression, only accessory muscle
use remained significantly associated with prolonged LOS.
Arising as a re-expression of the multiplicative effect on the geometric mean from a linear regression on log (LOS).
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and exposure to household smoke. Factors that signifi-
cantly reduced the odds of readmission were detection of
“any virus,” “any bacteria,” RSVand “RSVand HRV” on
NPS (Table 5). On multivariate regression, previous
respiratory hospitalization and exposure to household
smoke were factors that significantly increased the odds
of readmission but the presence of “any bacteria” and
RSV reduced the odds of readmission (Table 5). The
presence of any respiratory abnormality (i.e., presence of
cough, wheeze, or crackles) at 3 weeks was not associated
with the odds of respiratory readmissions (OR 1.2, 95%
CI: 0.6–3.0, P¼ 0.6).
DISCUSSION
In our study involving 232 Indigenous infants
hospitalized with bronchiolitis, we found that a higher
severity score on admission, particularly use of accessory
muscles, was associated with prolonged hospital stay. The
presence of a virus or viruses detected on hospitalization
TABLE 5—Analysis of Risk Factors for Respiratory Readmissions Within 6 Months (nmax¼204)
Univariate Multivariate
Factors present on admission OR 95%CI P-value OR 95%CI P-value
Continuous Median (respiratory readmit vs. first hospitalisation)
Age (months) 5.0 vs. 5.5 1.0 (0.9, 1.1) 0.9
Birth weight (kg) 3.0 vs. 3.0 0.8 (0.5, 1.3) 0.4
Gestational age (weeks) 38 vs. 38 0.9 (0.8, 1.0) 0.11 1.0 (0.9, 1.1) 0.5
Severity score on admission (points) 5 vs. 5 1.0 (0.9, 1.2) 0.6
Categorical n/N (%)
Gender
Female 15/72 (21%) 0.8 (0.4, 1.6) 0.5
Male 33/132 (25%) (reference)
Currently breastfed
Yes 42/173 (24%) 1.3 (0.5, 3.5) 0.6
No 6/31 (19%) (reference)
Previous respiratory hospitalisation
Yes 16/41 (39%) 2.6 (1.3, 5.5) 0.01 2.3 (1.0, 5.4) 0.05
No 32/163 (20%) (reference)
Mother smoked during pregnancy
Yes 25/114 (22%) 0.8 (0.4, 1.5) 0.5
No 23/87 (26%) (reference)
Exposed to household smoke
Yes 37/127 (29%) 2.4 (1.1, 5.1) 0.02 2.6 (1.0, 6.3) 0.04
No 11/76 (14%) (reference)
Antibiotics before hospitalisation
Yes 26/116 (22%) 0.9 (0.5, 1.7) 0.7
No 22/88 (25%) (reference)
Any virus detected
Yes 31/154 (20%) 0.5 (0.2, 1.0) 0.05
No 16/47 (34%) (reference)
RSV
Yes 9/89 (10%) 0.2 (0.1, 0.5) 0.0001 0.3 (0.1, 0.6) 0.001
No 38/112 (34%) (reference)
HRV
Yes 14/54 (26%) 1.2 (0.6, 2.5) 0.6
No 33/147 (22%) (reference)
RSV and HRV
Yes 23/128 (18%) 0.4 (0.2, 0.9) 0.02
No 25/76 (33%) (reference)
Adenovirus
Yes 3/12 (25%) 1.1 (0.3, 4.2) 0.9
No 44/189 (23%) (reference)
Any bacteria detected
Yes 25/138 (18%) 0.4 (0.2, 0.8) 0.008 0.4 (0.2, 0.9) 0.02
No 23/65 (35%) (reference)
Virus/Bacteria interaction 0.5
Virus negative/Bacteria negative 8/20 (40%) (reference)
Virus negative/Bacteria positive 8/27 (30%) 0.6 (0.2, 2.1) 0.5
Virus positive/Bacteria negative 14/44 (32%) 0.7 (0.2, 2.1) 0.5
Virus positive/Bacteria positive 17/110 (15%) 0.3 (0.1, 0.8) 0.01
On multivariate regression, previous respiratory hospitalisation and exposure to household smoke significantly increasing odds of readmission but
the presence of any bacteria and RSV reduced the odds of readmission.
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was not associated with poorer outcomes. Beyond
hospitalization, factors associated with presence of
cough at 3 weeks were previous respiratory hospitaliza-
tion and presence of bacteria. By 6 months, infants
previously hospitalized with a respiratory illness and
exposed to household smoke had an increased odds of
re-hospitalization for a respiratory illness. In contrast
however, infants with presence of RSV and culturable
bacteria detected in NPS had decreased odds of re-
hospitalization at 6 months. Further, infants who were
coughing at 3 weeks post-hospitalization were signifi-
cantly more likely to be diagnosed with bronchiectasis
a median of 13 months later.
Our study involved only Indigenous children as
recurrent hospitalizations for respiratory infections and
chronic suppurative lung disease is prevalent in our
setting.18 Indigenous children living in USA, Canada,
Australia and New Zealand share many similarities with
respect to the burden of respiratory illness.26 Thus,
we were interested in finding factors associated with
poorer clinical outcomes and possible future interven-
tion points. Studies on hospitalized bronchiolitis in
Canadian children found ethnicity, apnoea or respiratory
arrest prior to hospitalization or pulmonary consolida-
tion to have more complicated hospitalization.27
Further, previous RSV bronchiolitis hospitalization
was associated with chronic cough and recurrent
respiratory infections in early childhood.17
Well known or “traditional risk factors” associated
with severe bronchiolitis in infants include prematurity,
cardio-respiratory disease, and being Indigenous.3,28
In contrast, there are a few prospective studies which
examined other factors that prolonged LOS. In these
studies, factors significantly associated with prolonged
LOS were young age, increased work of breathing,
heart rate, respiratory rate, dehydration, hypoxia on
admission, SpO2 <94%, respiratory distress assessment
instrument (RDAI) score >11, apnoea, weight, RSV,
ethnicity, andwinter season.27,29–31 Retrospective studies
have described that RSV, ethnicity, congenital syn-
dromes, neuromuscular disorders and existing chronic
respiratory diseases were associated with prolonged
LOS.32 In our study, severity score on admission,
particularly use of accessory muscles, was the only
factor to prolong LOS, once other factors (n¼21) were
accounted for in the multivariate regression. None of the
previous studies however had dissectedwhich component
of the scoring system contributed the most to LOS.
Further, despite the many studies undertaken for
bronchiolitis, most scoring systems used were not
validated.6,29,32 Indeed the most commonly used system,
the RDAI score, has limited validity when systematically
examined.33 Within our study, we had validated the
scoring system used and showed good inter- and intra-
rater reliability.24
The type and number of viruses (particularly RSV
and HRV) did not significantly influence LOS in our
study. Our results are similar to some studies,9,11 but
dissimilar to others where RSV and/or HRV influenced
disease severity.8,34,35 Reasons for these variations are
likely multi-factorial including sample size, different
methodologies, sampling frame, age, number and
types of viruses investigated.11,12 We also found that
although respiratory bacteria (H. influenzae, S. pneumo-
niae, and M. catarrhalis) and/or viruses were common
(88%), their presence did not prolong LOS. While data
relating to LOS and type of virus detection has
been previously examined, none of these studies have
examined the influence of the presence of bacteria in
the upper airways. We found that the presence of
bacteria detected in the nasopharynx with or without
concurrent viruses did not influence LOS. Our finding
of high prevalence of concurrent bacteria with viruses
(i.e., 88%) in the children’s nasopharynx is similar to
that reported by Bisgaard and colleagues among young
children of asthmatic mothers with acute wheeze in a
non-hospitalised cohort.36
Beyond the hospital phase, our study reported several
novel outcomes. At 3 weeks post-hospitalisation, the
prevalence of respiratory symptoms in our study (20%)
was similar to other studies (18–25%).21,22,37 Few studies
however have prospectively recorded respiratory symp-
toms post-hospitalization, and no studies have examined
for predictors of persistent respiratory symptoms other-
wise known as “post-bronchiolitis syndrome.” While
presence of bacteria in the NPS on admission was not
significantly associated with persistence of cough at
3 weeks,36 chronic cough is the most common symptom
of an underlying lung disease and causes poorer quality
of life.38 In this study, persistent cough was however
a significant risk factor (OR 3.0, 95%CI 1.0–7.0,
P¼ 0.03) for CT-confirmed bronchiectasis 13 months
later. Bronchiectasis is particularly common in Indige-
nous infants in the USA, Australia and New Zealand and
hospitalization for respiratory disease is an independent
risk factor.18
In the context that early treatment of bacterial infections
in the lower airways prevents long-term lung damage,39,40
our post-hospitalization data is both novel and important in
high-risk population groups (e.g., Indigenous children). 18
Post-bronchiolitis syndrome is likely highly important
especially in high-risk populations. Our data raises an
important public health issue with respect to follow-up of
children with bronchiolitis, to optimise clinical care
beyond the immediate hospitalization phase to improve
long-term respiratory outcomes for high-risk populations.
We suggest that children should be clinically reviewed
between weeks 3–4 after hospital discharge to assess for
persistent symptoms and signs and managed accordingly.
There is currently no high quality evidence on the most
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appropriate intervention in any groups of children with
post-bronchiolitis syndrome.41 However, until further
evidence is available, we suggest the use of antibiotics
when the cough iswet and not improving in a group at high
risk of chronic suppurative lung disease, in line with the
treatment of protracted bacterial bronchitis.42
Our post-hospitalization data also showed that children
exposed to environmental tobacco smoke and those
previously hospitalized with a respiratory illness were
twice as likely to be readmitted with a respiratory illness
within 6 months of hospital discharge. Surprisingly, we
found that presence ofRSVon admission and “any bacteria”
significantly reduced the odds of re-hospitalization by
6 months post index hospitalization. Whether respiratory
readmissions in this population were related to the initial
bronchiolitis episode, a new infection or other causes can
only be postulated.Onepossible reason for this could be that
RSV detection is a marker (as opposed to a cause) for future
asthma and as the majority of paediatric asthma is mild,
having asthma is less likely to lead to re-hospitalisation
compared to a respiratory infection in our setting.
Our study has several limitations. Firstly, our sampling
frame is restricted to Indigenous children without the
well-known, traditional risk factors (e.g. chronic lung
disease, cardiac disease) andwho did not require intensive
care. Reasons for our sampling frame were discussed
above but it also means our data cannot be extrapolated to
the general population or to non-hospitalized infants.
Secondly, we did not exclude infants that had been
hospitalized previously; however, exclusion of these
infants did not alter our main results. Thirdly, 87% of
children received antibiotics during hospitalization. This
may have impacted on nasopharyngeal bacterial carriage,
however removing these children did not alter our
main results. Fourthly, the children were systematically
reviewed only at one time point, that is, at 3 weeks post-
hospitalization. The decision by the treating paediatri-
cians who reviewed these infants at a median of 7 months
post-hospitalization to subject the child to a chest CT
scan was based on clinical assessments, not systemized
and thus subject to external biases. Thus, we could not
systematically analyze the factors on admission that are
associated with future development of bronchiectasis.
Also, while long-term, prospective, follow-up studies in
high-risk populations are required, we cannot unethically
subject all children to a chest CT (given the known risk
of radiation in young children).
CONCLUSION
In the first prospective study of Indigenous infants
hospitalized with bronchiolitis with post-hospitalization
data at 3 weeks and 6 months, we found that the severity
score on admission, particularly accessorymuscle use,was
the sole factor associated with prolonged LOS once other
factors (clinical and microbiological) were accounted for.
Persistent respiratory symptoms at 3 weeks increased
the risk of detecting bronchiectasis and factors associated
with persistent symptoms were prior hospitalisation for a
respiratory illness and presence of bacteria on the NPS
on admission. Thus, clinical review, with early treatment
when necessary, should be undertaken in populations at
high risk for chronic respiratory disease. Follow-up studies
beyond 6 months are necessary to consolidate our findings
and determine intervention points that can reduce the high
burden of respiratory diseases in at-risk populations.
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